Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 21, 2026

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

Solitary plasmacytoma.

Roi Dagan1, Christopher G Morris, Jessica Kirwan

  • 1Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida, USA.

American Journal of Clinical Oncology
|July 14, 2009
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sustained Locoregional Control With Deintensified Chemoradiotherapy for HPV Oropharyngeal Carcinoma.

JAMA otolaryngology-- head & neck surgery·2026
Same author

Ten-year outcomes for image-guided moderately hypofractionated proton therapy for prostate cancer.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Long-Term Outcomes of Consolidative Proton Therapy for Pediatric Classical Hodgkin Lymphoma.

International journal of particle therapy·2026
Same author

Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial.

Lancet (London, England)·2025
Same author

RBE-Guided Treatment Planning, LET Optimization, and Implications of Proton Arc Therapy for the Sparing of Nervous Tissue in Head and Neck Proton Therapy.

Cancers·2025
Same author

A Systematic Study on Local Failure Events Post Chemoradiation Therapy for Cervical Cancer: Understanding the Impact of Baseline Lateral Anatomic Compartment Involvement.

International journal of radiation oncology, biology, physics·2025
Same journal

Care Patterns and Gastric Cancer-Related Outcomes in Patients With Pathogenic/Likely Pathogenic Germline CDH1 Variants: A 14-Year Single-Center Analysis.

American journal of clinical oncology·2026
Same journal

Upper Extremity Lymphedema​​​: Performance of a Risk Prediction Model in Women Undergoing Surgery for Breast Cancer.

American journal of clinical oncology·2026
Same journal

Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for the Use of Radiation in the Prevention and Treatment of Heterotopic Ossification (HO).

American journal of clinical oncology·2026
Same journal

Stereotactic Body Radiation Therapy Combined With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Comprehensive Single-Arm Meta-Analysis Approach.

American journal of clinical oncology·2026
Same journal

Emergence of Single-Week Adjuvant Radiation Therapy for Early-Stage Breast Cancer in the United States.

American journal of clinical oncology·2026
Same journal

Early Versus Delayed Pancreatic Enzyme Replacement Therapy After Pancreatic Cancer Surgery: A Real-World Cohort Study.

American journal of clinical oncology·2026
See all related articles

Radiotherapy (RT) effectively controls solitary plasmacytoma locally. However, patients with solitary plasmacytoma of bone face a higher risk of progressing to multiple myeloma, impacting survival compared to extramedullary plasmacytoma patients.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Hematology

Background:

  • Solitary plasmacytoma is a rare plasma cell neoplasm.
  • Treatment strategies aim for local control and prevention of systemic progression.
  • Radiotherapy is a primary treatment modality for solitary plasmacytoma.

Purpose of the Study:

  • To evaluate the long-term outcomes of patients treated with definitive radiotherapy for solitary plasmacytoma.
  • To compare outcomes between solitary plasmacytoma of bone (SPB) and extramedullary plasmacytoma (EMP).

Main Methods:

  • Retrospective analysis of 32 patients with SPB (22) and EMP (10) treated between 1963 and 2006.
  • Median radiotherapy dose of 42.7 Gy (range, 15-54 Gy) in 25 fractions (range, 1-32 fractions).
  • No adjuvant chemotherapy was administered; median follow-up was 10.1 years.

More Related Videos

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Related Experiment Videos

Last Updated: Jun 21, 2026

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Main Results:

  • 10-year local-control rate was 87%, with local recurrence associated with SPB size ≥ 5 cm.
  • 10-year multiple myeloma-free survival rates were 30% for SPB, 90% for EMP, and 50% overall.
  • 10-year cause-specific survival was 65% for SPB versus 100% for EMP (P = 0.006).

Conclusions:

  • Moderate-dose radiotherapy achieves high local control rates for solitary plasmacytoma.
  • Solitary plasmacytoma of bone carries a significantly higher risk of progression to multiple myeloma.
  • Extramedullary plasmacytoma demonstrates superior survival outcomes compared to bone plasmacytoma following radiotherapy.